Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy

Cancer Lett. 2015 Jan 28;356(2 Pt B):517-24. doi: 10.1016/j.canlet.2014.09.025. Epub 2014 Oct 6.

Abstract

The expression of organic anion transporting polypeptides (OATPs) was elucidated in cell lines from small cell lung cancer (SCLC) and lung carcinoids and in paraffin-embedded samples from primary and metastatic SCLCs. We found a strong relationship between OATP expression and the origin of the cells, as cells from primary or metastatic SCLC and carcinoid tumors differ with respect to OATP levels. OATP4A1 is most prominent in non-malignant lung tissue and in all SCLC and carcinoid cell lines and tissues, OATP5A1 is most prominent in metastatic cells, and OATP6A1 is most prominent in SCLC cell lines and tumors. Treatment with topotecan, etoposide and cisplatin caused significant changes in the expression patterns of OATP4A1, OATP5A1, OATP6A1, chromogranin and synaptophysin. This effect was also evident in GLC-14 cells from an untreated SCLC patient before chemotherapy compared to GLC-16/-19 chemoresistant tumor cells from this patient after therapy. mRNA expression of OATP4A1, 5A1 and 6A1 correlates with protein expression as confirmed by quantitative microscopic image analysis and Western blots. OATPs might be novel biomarkers for tumor progression and the development of metastasis in SCLC patients.

Keywords: Chemotherapy; Neurogenic marker; OATP gene expression; Organic anion transporting polypeptide (OATP); Small cell lung cancer (SCLC).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Blotting, Western
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / secondary
  • Chromogranins / genetics
  • Chromogranins / metabolism
  • Cisplatin / administration & dosage
  • Drug Resistance, Neoplasm
  • Etoposide / administration & dosage
  • Fluorescent Antibody Technique
  • Humans
  • Immunoenzyme Techniques
  • Lung / metabolism
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Organic Anion Transporters / genetics
  • Organic Anion Transporters / metabolism*
  • RNA, Messenger / genetics
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Small Cell Lung Carcinoma / drug therapy
  • Small Cell Lung Carcinoma / genetics*
  • Small Cell Lung Carcinoma / secondary
  • Synaptophysin / genetics
  • Synaptophysin / metabolism
  • Topotecan / administration & dosage
  • Tumor Cells, Cultured

Substances

  • Biomarkers, Tumor
  • Chromogranins
  • Organic Anion Transporters
  • RNA, Messenger
  • SYP protein, human
  • Synaptophysin
  • Etoposide
  • Topotecan
  • Cisplatin